Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.40 USD
-0.07 (-4.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Cognition Therapeutics, Inc.'s return on equity, or ROE, is -251.23% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that CGTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CGTX 1.40 -0.07(-4.76%)
Will CGTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
50 Day Moving Average Resistance appears for CGTX after 4.76% move
CGTX Fell Below 50 Day Moving Average on September 19
Is CGTX primed for upward momentum? 50 Day Moving Average Support shows up after crashing 8.7%
Non-ADX 1,2,3,4 Bullish appears for CGTX after 4.55% move
Is CGTX heading for a slide? New Downtrend shows up after plummeting 29.03%